McKesson reported FY2026 revenue of $403.4 billion and FY2026 operating income of $6.2 billion. The thesis depends on pharma distribution scale, specialty growth, working capital, margins and cash conversion.
The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.
